Biocept Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Biocept (BIOC) Tops Q1 EPS by 19c
May 12, 2021 4:24 PM EDTBiocept (NASDAQ: BIOC) reported Q1 EPS of $0.19, $0.19 better than the analyst estimate of $0.00. Revenue for the quarter came in at $17.8 million versus the consensus estimate of $13.67 million.
We are reporting profitability for the second consecutive quarter on revenues of $17.8 million, as our dedicated Biocept team continued to serve our community with COVID-19 RT-PCR testing featuring exceptional customer service and rapid turnaround times, said Michael Nall, Biocepts President and CEO. These outstanding financial results support further advancements with our core oncology business and more specifically our focus on neuro-oncology as we build for a strong... More
